Patterns of heart injury in COVID‐19 and relation to outcome

Mishra, Ajay Kumar; Sahu, Kamal Kant; Lal, Amos; Sargent, Jennifer

doi:10.1002/jmv.25847

Cited by 34 publications

(34 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Advanced age was associated with higher mortality in this study with a reported case fatality of 12.8%, 20.2% in patients above age group of 70 and 80 simultaneously. Across all studies cardiovascular risk factors like advanced age, hypertension, diabetes, coronary artery disease, heart failure, atrial fibrillation, cerebrovascular disease have been reported to be associated with increased mortality [67,68]. As shown in image one these factors have been independently shown to be associated with worsening disease severity, bilateral confluent lung involvement on CT chest involvement of multiple organs, requirement of invasive and noninvasive ventilation, presence of cardiac injury, and mortality [69][70][71].…”

Section: Cardiovascular Patients With Covid-19 Diseasementioning

confidence: 87%

COVID-2019: update on epidemiology, disease spread and management

Sahu

Mishra

Lal

2020

Monaldi Arch Chest Dis

Self Cite

View full text Add to dashboard Cite

With each passing day, more cases of Coronavirus disease (COVID-2019) are being detected and unfortunately the fear of novel corona virus 2019 (2019-nCoV) becoming a pandemic disease has come true. Constant efforts at individual, national, and international level are being made in order to understand the genomics, hosts, modes of transmission and epidemiological link of nCoV-2019. As of now, whole genome sequence of the newly discovered coronavirus has already been decoded. Genomic characterization nCoV-2019 have shown close homology with batderived severe acute respiratory syndrome (SARS)-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21. Structural analysis of the receptor binding site has confirmed that 2019-nCoV binds with the same ACE 2 receptor protein as human SARS virus. Compared to the previous coronavirus outbreaks, the overall mortality rate is relatively low for COVID-2019 (2-3%). Suspected cases must be quarantined till their test comes positive or they clear infection. At present, treatment of COVID-2019 is mostly based on the knowledge gained from the SARS and MERS outbreaks. Remdesivir, originally develop as a treatment for Ebola virus disease and Marburg virus infections, is being studied for its effectiveness against 2019-nCoV infection. Many other antiviral agents and vaccines are being tested but most of them are in phase I or II and hence unlikely to be of any benefit immediately with regards to current outbreak. Hence, the standard infection control techniques and preventive steps for healthy individuals and supportive care for the confirmed cases is the best available strategy to deal with current viral outbreak.

show abstract

Section: Cardiovascular Patients With Covid-19 Diseasementioning

confidence: 87%

COVID-2019: update on epidemiology, disease spread and management

Sahu

Mishra

Lal

2020

Monaldi Arch Chest Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Jodele et al recently reported in the largest ever cohort series that terminal complement blockage with C5 inhibitor eculizumab significantly improved 1-yr post-allo-HSCT survival in patients with high-risk TA-TMA [46]. In COVID-19 disease, there is evidence suggesting complement dysregulation related TMA as one of the important pathophysiological mechanism in addition to or as part of thromboinflammation [25,27,47].…”

Section: Complement Activation In Covid-19mentioning

confidence: 99%

Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19

Wang

Sahu

Černý

2020

J Thromb Thrombolysis

Self Cite

View full text Add to dashboard Cite

Coronavirus disease-2019 (COVID-19) is a rapidly evolving health crisis caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is a novel disease entity and we are in a learning phase with regards to the pathogenesis, disease manifestations, and therapeutics. In addition to the primary lung injury, many patients especially the ones with moderate to severe COVID-19 display evidence of endothelial damage, complement activation, which leads to a pro-coagulable state. While there are still missing links in our understanding, the interplay of endothelium, complement system activation, and immune response to the SARS-CoV-2 virus is a surprisingly major factor in COVID-19 pathogenesis. One could envision COVID-19 becoming a novel hematological syndrome. This review is to discuss the available literature with regards to the involvement of the complement system, and coagulation cascade and their interaction with endothelium.

show abstract

“…This has been identified as pathophysiologic basis of acute cardiac injury in COVID-19 patients, with non-ischemic injury (secondary to cytokine storm, stress cardiomyopathy, viral myocarditis, or hypoxia induced cardiac myocyte death) being the predominant mechanism. 18 Abnormal troponin, in particular, has been found in more than half of the patients diagnosed with COVID-19. Thus, clinicians are only advised to measure troponin if acute myocardial infarction is suspected; abnormal troponin alone should not be considered evidence of acute myocardial infarction without other corroborating clinical evidence.…”

Section: Cardiac Markers and Prognosismentioning

confidence: 99%

Coronavirus disease‐19 and cardiovascular disease: A risk factor or a risk marker?

Liu

Virani

Alam

et al. 2020

Reviews in Medical Virology

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus-2 causes the clinical syndrome of coronavirus disease of 2019 (COVID-19) which has become a global pandemic resulting in significant morbidity and mortality. While the virus primarily affects the respiratory system, it also causes a wide variety of complex cardiac manifestations such as acute myopericarditis, acute coronary syndrome, congested heart failure, cardiogenic shock and cardiac arrhythmias. There are numerous proposed mechanisms of cardiac injury, including direct cellular injury, pro-inflammatory cytokine storm, myocardial oxygen-demand mismatch, and systemic inflammation causing multi-organ failure. Additionally, medications commonly used to treat COVID-19 patients have various cardiovascular side effects. We aim to provide a succinct review about the pathophysiology and cardiac manifestations of COVID-19, as well as treatment considerations and the various adaptations made to the current healthcare structure as a result of the pandemic.

show abstract

Patterns of heart injury in COVID‐19 and relation to outcome

Cited by 34 publications

References 8 publications

COVID-2019: update on epidemiology, disease spread and management

COVID-2019: update on epidemiology, disease spread and management

Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19

Coronavirus disease‐19 and cardiovascular disease: A risk factor or a risk marker?

Contact Info

Product

Resources

About